HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potassium, Hypertension/Stroke Risk Reduction Health Claim Cleared By FDA

This article was originally published in The Tan Sheet

Executive Summary

Functional food manufacturers could look to create a new niche market following FDA's authorization of a high blood pressure and stroke risk-reduction health claim for foods high in potassium.

You may also be interested in...



Functional Beverages Stimulate Natural Products Market Growth - Analysts

The natural products market, fueled by nutritionally fortified foods such as functional beverages, meal replacement bars and soy products, will continue to demonstrate strong annual growth in the mid-teens over the next several years, analysts predict.

Omega-3/Heart Disease Qualified Supplement Health Claim Allowed

Dietary supplements bearing a qualified health claim for omega-3 fatty acids and coronary heart disease risk reduction must recommend a maximum daily intake of 2 g EPA and DHA, FDA announced Oct. 31.

Folic Acid Qualified Health Claims Based On IoM Findings Allowed By CFSAN

Dietary supplements may carry qualified health claims regarding the amount and sources of folic acid effective in reducing the risk of neural tube defects, FDA announces Oct. 10. The Center for Food Safety & Applied Nutrition's decision is in response to one of the four health claims at issue in the Pearson v. Shalala case.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel